Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years at the time of giving consent to participate.
• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed through laboratory testing of tissue or cell samples.
• People whose cancer cannot be surgically removed and has either spread or is locally advanced, and has continued to grow after at least one previous standard cancer treatment, or for whom standard treatment was not suitable or not tolerated.
• People who have at least one tumour that can be measured using standard imaging criteria.
• People whose tumour tissue tests positive for certain proteins — either mesothelin and/or MUC1 (for one treatment arm), or claudin 18.2 and/or MUC1 (for another treatment arm) — based on laboratory testing of a tissue sample (confirm with trial site for specific thresholds).
• People who are in reasonably good general health, able to carry out light activity and care for themselves, as assessed by a standard health scale (ECOG score of 0 or 1).
• People whose blood counts, liver function, and kidney function meet the minimum levels required by the trial.
• People with a life expectancy of at least 12 weeks.
• People who are not pregnant, as confirmed by a test, and who agree to use effective contraception during the trial and for a set period afterwards.
• People who are able to understand the study and are willing to sign a written consent form.

Who may not be able to join:

• People with active or untreated cancer that has spread to the brain or the lining of the brain or spinal cord.
• People with a serious, uncontrolled infection at the time of enrolment.
• People with active hepatitis B or hepatitis C with detectable levels of the virus in their blood, or an uncontrolled HIV infection.
• People who have previously had a bone marrow transplant using donor cells, or a transplanted solid organ.
• People who have received a gene-modified cell therapy (such as CAR-T or CAR-NK therapy) within the past 6 months, or who have previously received treatment targeting the same proteins this trial targets.
• People who require ongoing use of immune-suppressing medicines, such as long-term steroid use above a basic maintenance dose.
• People with serious heart conditions, such as a recent heart attack, an uncontrolled irregular heartbeat, or severe heart failure, within a timeframe defined by the trial.
• People with an active autoimmune disease that has required systemic treatment within the past 2 years (hormone or vitamin replacement therapy is generally allowed — confirm with trial site).
• People who are pregnant or breastfeeding.
• People with a medical, psychiatric, or personal situation that, in the treating doctor's judgement, could affect safe participation in the trial or the reliability of results.

Important: Always verify eligibility with the trial site directly before applying.